慢性脑室内注射1-甲基-4-苯基吡啶鎓作为帕金森病的渐进模型。
Chronic intraventricular administration of 1-methyl-4-phenylpyridinium as a progressive model of Parkinson's disease.
作者信息
Sonsalla Patricia K, Zeevalk Gail D, German Dwight C
机构信息
Department of Neurology, Robert Wood Johnson Medical School/UMDNJ, 675 Hoes Lane, Piscataway, NJ 08854, USA.
出版信息
Parkinsonism Relat Disord. 2008;14 Suppl 2(Suppl 2):S116-8. doi: 10.1016/j.parkreldis.2008.04.008. Epub 2008 Jun 25.
Abstract
Animal models of Parkinson's disease (PD) that more closely exhibit the chronic neuropathology seen in the human condition are needed in order to reveal processes involved with progressive neurodegeneration and for testing potential interventions for retarding dopamine (DA) neuronal loss. Here we describe the recently developed chronic rat model of PD in which 1-methyl-4-phenylpyridinium ion (MPP(+)) is infused chronically into the lateral cerebral ventricle. We review features of this model that include loss of nigral DA neurons, swollen and abnormal mitochondria, striatal inclusion-like bodies and microgliosis. Advantages as well as limitations of the model are addressed.
摘要
为了揭示与进行性神经退行性变相关的过程以及测试延缓多巴胺（DA）神经元丢失的潜在干预措施，需要更紧密地展现人类帕金森病（PD）慢性神经病理学特征的动物模型。在此，我们描述了最近开发的慢性大鼠PD模型，其中1-甲基-4-苯基吡啶离子（MPP(+)）被长期注入大脑侧脑室。我们回顾了该模型的特征，包括黑质DA神经元丢失、线粒体肿胀和异常、纹状体包涵体样小体以及小胶质细胞增生。还讨论了该模型的优点和局限性。
相似文献
1
Chronic intraventricular administration of 1-methyl-4-phenylpyridinium as a progressive model of Parkinson's disease.
Parkinsonism Relat Disord. 2008;14 Suppl 2(Suppl 2):S116-8. doi: 10.1016/j.parkreldis.2008.04.008. Epub 2008 Jun 25.
2
Rat model of Parkinson's disease: chronic central delivery of 1-methyl-4-phenylpyridinium (MPP+).
Exp Neurol. 2006 Jul;200(1):172-83. doi: 10.1016/j.expneurol.2006.02.002. Epub 2006 Mar 20.
3
A quantitative approach to developing Parkinsonian monkeys (Macaca fascicularis) with intracerebroventricular 1-methyl-4-phenylpyridinium injections.
J Neurosci Methods. 2015 Aug 15;251:99-107. doi: 10.1016/j.jneumeth.2015.05.008. Epub 2015 May 21.
4
IL-17A exacerbates neuroinflammation and neurodegeneration by activating microglia in rodent models of Parkinson's disease.
Brain Behav Immun. 2019 Oct;81:630-645. doi: 10.1016/j.bbi.2019.07.026. Epub 2019 Jul 24.
5
7-nitroindazole protects striatal dopaminergic neurons against MPP+-induced degeneration: an in vivo microdialysis study.
Ann N Y Acad Sci. 2006 Nov;1089:462-71. doi: 10.1196/annals.1386.015.
6
Chronic effects of single intrastriatal injections of 6-hydroxydopamine or 1-methyl-4-phenylpyridinium studied by microdialysis in freely moving rats.
Brain Res. 1995 Oct 16;695(2):151-7. doi: 10.1016/0006-8993(95)00705-u.
7
Targeting microglial NLRP3 in the SNc region as a promising disease-modifying therapy for Parkinson's disease.
Brain Behav. 2022 Nov;12(11):e2784. doi: 10.1002/brb3.2784. Epub 2022 Oct 5.
8
Direct intranigral injection of dopaminochrome causes degeneration of dopamine neurons.
Neurosci Lett. 2016 Jan 26;612:178-184. doi: 10.1016/j.neulet.2015.12.028. Epub 2015 Dec 15.
9
1-Methyl-4-phenylpyridinium affects fast axonal transport by activation of caspase and protein kinase C.
Proc Natl Acad Sci U S A. 2007 Feb 13;104(7):2442-7. doi: 10.1073/pnas.0611231104. Epub 2007 Feb 7.
10
Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat.
Neurobiol Dis. 2002 Jul;10(2):119-27. doi: 10.1006/nbdi.2002.0507.
引用本文的文献
1
Identification of copper metabolism-related markers in Parkinson's disease.
Ann Med. 2024 Dec;56(1):2425064. doi: 10.1080/07853890.2024.2425064. Epub 2024 Nov 18.
2
Adenosine A Receptor Blockade Provides More Effective Benefits at the Onset Rather than after Overt Neurodegeneration in a Rat Model of Parkinson's Disease.
Int J Mol Sci. 2024 Apr 30;25(9):4903. doi: 10.3390/ijms25094903.
3
UBL3 Interacts with Alpha-Synuclein in Cells and the Interaction Is Downregulated by the EGFR Pathway Inhibitor Osimertinib.
Biomedicines. 2023 Jun 10;11(6):1685. doi: 10.3390/biomedicines11061685.
4
Zfra Inhibits the TRAPPC6AΔ-Initiated Pathway of Neurodegeneration.
Int J Mol Sci. 2022 Nov 22;23(23):14510. doi: 10.3390/ijms232314510.
5
Altered expression of miR-29a-3p and miR-34a-5p by specific inhibition of GSK3β in the MPP treated SH-SY5Y Parkinson's model.
Noncoding RNA Res. 2022 Jan 7;7(1):1-6. doi: 10.1016/j.ncrna.2021.12.004. eCollection 2022 Mar.
6
Characteristics of the mitochondrial and cellular uptake of MPP+, as probed by the fluorescent mimic, 4'I-MPP.
PLoS One. 2018 Aug 23;13(8):e0197946. doi: 10.1371/journal.pone.0197946. eCollection 2018.
7
Growth Factors and Neuroglobin in Astrocyte Protection Against Neurodegeneration and Oxidative Stress.
Mol Neurobiol. 2019 Apr;56(4):2339-2351. doi: 10.1007/s12035-018-1203-9. Epub 2018 Jul 7.
8
Intracerebroventricularly-administered 1-methyl-4-phenylpyridinium ion and brain-derived neurotrophic factor affect catecholaminergic nerve terminals and neurogenesis in the hippocampus, striatum and substantia nigra.
Neural Regen Res. 2018 Apr;13(4):717-726. doi: 10.4103/1673-5374.230300.
9
P-Glycoprotein Transport of Neurotoxic Pesticides.
J Pharmacol Exp Ther. 2015 Oct;355(1):99-107. doi: 10.1124/jpet.115.226373. Epub 2015 Aug 13.
10
2, 2'- and 4, 4'-Cyanines are transporter-independent in vitro dopaminergic toxins with the specificity and mechanism of toxicity similar to MPP⁺.
J Neurochem. 2015 Nov;135(4):755-67. doi: 10.1111/jnc.13201. Epub 2015 Aug 12.
本文引用的文献
1
Characterization of intracellular elevation of glutathione (GSH) with glutathione monoethyl ester and GSH in brain and neuronal cultures: relevance to Parkinson's disease.
Exp Neurol. 2007 Feb;203(2):512-20. doi: 10.1016/j.expneurol.2006.09.004. Epub 2006 Oct 17.
2
Rat model of Parkinson's disease: chronic central delivery of 1-methyl-4-phenylpyridinium (MPP+).
Exp Neurol. 2006 Jul;200(1):172-83. doi: 10.1016/j.expneurol.2006.02.002. Epub 2006 Mar 20.
3
Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein.
Proc Natl Acad Sci U S A. 2005 Mar 1;102(9):3413-8. doi: 10.1073/pnas.0409713102. Epub 2005 Feb 16.
4
Enhanced substantia nigra mitochondrial pathology in human alpha-synuclein transgenic mice after treatment with MPTP.
Exp Neurol. 2004 Apr;186(2):158-72. doi: 10.1016/S0014-4886(03)00342-X.
5
Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment.
Neuroscience. 2001;106(3):589-601. doi: 10.1016/s0306-4522(01)00295-0.
6
Chronic systemic pesticide exposure reproduces features of Parkinson's disease.
Nat Neurosci. 2000 Dec;3(12):1301-6. doi: 10.1038/81834.
7
Abnormal mitochondrial morphology in sporadic Parkinson's and Alzheimer's disease cybrid cell lines.
Exp Neurol. 2000 Mar;162(1):37-50. doi: 10.1006/exnr.2000.7333.
8
Neuropathological study on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine of the crab-eating monkey.
Acta Neuropathol. 1988;75(4):370-6. doi: 10.1007/BF00687790.
9
Ultrastructural changes of the substantia nigra, ventral tegmental area and striatum in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice.
Res Commun Chem Pathol Pharmacol. 1990 Mar;67(3):307-20.
Zotero 插件